Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  Explanatory Notes: (1) The number in Rows 5, 7 and 9 consists of (i) 1,062,500 shares of Common Stock held directly by the Reporting Person, (ii) 431,250 shares of Common Stock held by 0865546 B.C. Ltd., a company over which the Reporting Person has sole voting and dispositive power, (iii) 50,000 shares of Common Stock issuable upon exercise of stock options that have vested and are currently exercisable (the "Vested Options"), and (iv) 750,000 shares of Common Stock issuable upon exercise of performance warrants (the "Performance Warrants") that have vested and are currently exercisable (the "Vested Warrants"), and excludes 250,000 shares of Common Stock issuable upon exercise of Performance Warrants that have not yet vested and will not vest until the submission of a 510(k) application to the U.S. Food and Drug Administration (the "Unvested Warrants"). (2) The percentage in Row 11 is calculated based on (i) 27,397,164 shares of Common Stock outstanding as of August 17, 2026, (ii) 50,000 shares of Common Stock issuable upon exercise of the Vested Options held by the Reporting Person, and (iii) 750,000 shares of Common Stock issuable upon exercise of the Vested Warrants held by the Reporting Person, in each case deemed to be outstanding for the purpose of computing the Reporting Person's percentage ownership pursuant to Rule 13d-3(d)(1)(i) under the Act. The Unvested Warrants are excluded from this calculation.


SCHEDULE 13G



 
David Bogart
 
Signature:/s/ David Bogart
Name/Title:David Bogart
Date:08/17/2026